Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 15/20 | 0.37 |
| ▸ | F11 | P03951 | 8/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.37 |
| ▸ | PLG | P00747 | 3/20 | 0.37 |
| ▸ | PLAU | P00749 | 3/20 | 0.37 |
| ▸ | F7 | P08709 | 3/20 | 0.37 |
| ▸ | TPSB2 | P20231 | 3/20 | 0.37 |
| ▸ | EGFR | P00533 | 4/20 | 0.37 |
| ▸ | BTK | Q06187 | 3/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | F9 | P00740 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 2/20 | 0.35 |
| ▸ | PLAT | P00750 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29122130 | 0.91 | CFD (0.38) | CFDF11KLKB1PLGPLAU | |
| SCHEMBL29340562 | 0.90 | CFD (0.41) | CFDEGFRBTK | |
| SCHEMBL29122838 | 0.89 | CFD (0.38) | CFDF11KLKB1PLGPLAU | |
| SCHEMBL29122664 | 0.89 | CFD (0.40) | CFDF11KLKB1PLGPLAU | |
| SCHEMBL29121851 | 0.88 | CFD (0.37) | CFDF11KLKB1PLGPLAU | |
| SCHEMBL29345883 | 0.87 | EGFR (0.35) | CFDEGFRBTK | |
| SCHEMBL29122662 | 0.87 | CFD (0.39) | CFDF11KLKB1PLGPLAU | |
| SCHEMBL29121999 | 0.86 | GSK3B (0.42) | CFDF11KLKB1PLGPLAU | |
| SCHEMBL29122164 | 0.84 | KDM4C (0.36) | KLKB1EGFRBTKF10 | |
| SCHEMBL29121608 | 0.84 | CFD (0.38) | CFDF11KLKB1PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| CN-117120419-A | KLK5 bicyclic heteroaromatic inhibitors | 拜奥克里斯特制药公司 | 2023-11-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | CFD 3529/4885F11 1832/4885KLKB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.